MARKET

PRTA

PRTA

Prothena Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.12
+1.49
+6.87%
Opening 15:10 05/14 EDT
OPEN
21.63
PREV CLOSE
21.63
HIGH
23.23
LOW
21.30
VOLUME
113.82K
TURNOVER
--
52 WEEK HIGH
28.66
52 WEEK LOW
9.25
MARKET CAP
1.02B
P/E (TTM)
-8.3013
1D
5D
1M
3M
1Y
5Y
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Zacks · 1d ago
--Oppenheimer Adjusts Prothena PT to $40 From $35, Maintains Outperform Rating
MT Newswires · 2d ago
Prothena (PRTA) Receives a Buy from Oppenheimer
Oppenheimer analyst Jay Olson assigned a Buy rating to Prothena (PRTA) yesterday and set a price target of $40.00. The company's shares closed last
SmarterAnalyst · 2d ago
8-K: PROTHENA CORP PUBLIC LTD CO
(EDGAR Online via COMTEX) -- 0001559053FALSE00015590532021-05-112021-05-1100015590532020-11-042020-11-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
Prothena EPS misses by $0.37, misses on revenue
Prothena (PRTA): Q1 GAAP EPS of -$0.91 misses by $0.37.Revenue of $0.16M (+14.3% Y/Y) misses by $8.5M.Press Release
Seekingalpha · 2d ago
Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update
Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million...
GlobeNewswire · 2d ago
Prothena Q1 Net Loss Widens, Revenue Rises
MT Newswires · 3d ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRTA. Analyze the recent business situations of Prothena Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRTA stock price target is 31.86 with a high estimate of 43.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 203
Institutional Holdings: 37.05M
% Owned: 84.31%
Shares Outstanding: 44.18M
TypeInstitutionsShares
Increased
24
1.25M
New
27
3.73M
Decreased
51
5.02M
Sold Out
24
1.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.80%
Pharmaceuticals & Medical Research
+1.24%
Key Executives
Non-Executive Chairman/Independent Director
Lars Ekman
President/Chief Executive Officer/Director
Gene Kinney
Chief Financial Officer/Chief Operating Officer
Tran Nguyen
Chief Accounting Officer/Controller
Karin Walker
Chief Scientific Officer
Wagner Zago
Other
Hideki Garren
Other
Carol Karp
Other
Brandon Smith
Other
Radhika Tripuraneni
Secretary
Michael Malecek
Independent Director
Paula Cobb
Independent Director
Richard Collier
Independent Director
Shane Cooke
Independent Director
K. Anders Harfstrand
Independent Director
Christopher Henney
Independent Director
Oleg Nodelman
Independent Director
Dennis Selkoe
No Data
About PRTA
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Webull offers kinds of Prothena Corporation PLC stock information, including NASDAQ:PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.